anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.89 [0.81, 0.98]< 144%24 studies (24/-)98.8 %some concerncritical moderatecrucial-
death or transfer to ICU 0.79 [0.50, 1.24]< 10%2 studies (2/-)84.9 %some concernnot evaluable moderatecrucial-
deaths 0.90 [0.84, 0.95]< 134%59 studies (59/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.78 [0.61, 1.00]< 146%8 studies (8/-)97.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.68 [0.55, 0.85]< 146%17 studies (17/-)100.0 %some concernlow moderateimportant-
clinical improvement 1.16 [1.05, 1.28]> 127%19 studies (19/-)99.8 %some concernlow moderateimportant-
clinical improvement (14-day) 1.51 [1.01, 2.26]> 125%4 studies (4/-)97.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.29 [0.92, 1.81]> 156%5 studies (5/-)93.3 %some concernserious moderateimportant-
clinical improvement (7-day) 0.86 [0.58, 1.28]> 10%2 studies (2/-)23.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [1.05, 1.26]> 14%12 studies (12/-)99.8 %some concernlow moderateimportant-
death or ventilation 0.90 [0.84, 0.97]< 156%17 studies (17/-)99.8 %some concernlow moderateimportant-
hospital discharge 1.08 [1.01, 1.16]> 141%10 studies (10/-)98.6 %some concernlow moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.84 [0.74, 0.96]< 114%21 studies (21/-)99.4 %some concernlow moderateimportant1
radiologic improvement (14-day) 3.53 [1.19, 10.46]> 10%2 studies (2/-)98.9 %some concernnot evaluable moderateimportant-
viral clearance 3.00 [0.87, 10.35]> 192%4 studies (4/-)95.9 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.18 [0.54, 2.54]> 183%2 studies (2/-)66.0 %some concernnot evaluable moderateimportant-
viral clearance by day 14 6.64 [0.42, 104.56]> 195%3 studies (3/-)90.9 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.10 [0.48, 2.49]> 142%2 studies (2/-)58.7 %some concernnot evaluable moderateimportant-
ICU admission 0.64 [0.46, 0.90]< 135%12 studies (12/-)99.5 %some concerncritical moderatenon important-
recovery 1.25 [0.72, 2.19]> 144%3 studies (3/-)78.5 %some concernnot evaluable moderatenon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %lownot evaluable highimportant-
serious adverse events 1.11 [0.97, 1.26]< 15%20 studies (20/-)6.7 %some concernlow moderateimportant-
superinfection 0.70 [0.46, 1.07]< 153%4 studies (4/-)95.0 %some concernnot evaluable moderateimportant-
adverse events 1.25 [1.01, 1.55]< 121%13 studies (13/-)2.1 %some concerncritical moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.